XML 99 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Earnings (USD $)
In Millions, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 28, 2014
Dec. 29, 2013
Dec. 30, 2012
Sales to customers $ 74,331us-gaap_SalesRevenueGoodsNet $ 71,312us-gaap_SalesRevenueGoodsNet $ 67,224us-gaap_SalesRevenueGoodsNet
Cost of products sold 22,746us-gaap_CostOfGoodsSold 22,342us-gaap_CostOfGoodsSold 21,658us-gaap_CostOfGoodsSold
Gross profit 51,585us-gaap_GrossProfit 48,970us-gaap_GrossProfit 45,566us-gaap_GrossProfit
Selling, marketing and administrative expenses 21,954us-gaap_SellingGeneralAndAdministrativeExpense 21,830us-gaap_SellingGeneralAndAdministrativeExpense 20,869us-gaap_SellingGeneralAndAdministrativeExpense
Research and development expense 8,494us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost 8,183us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost 7,665us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
In-process research and development 178us-gaap_ResearchAndDevelopmentInProcess 580us-gaap_ResearchAndDevelopmentInProcess 1,163us-gaap_ResearchAndDevelopmentInProcess
Interest income (67)us-gaap_InvestmentIncomeInterest (74)us-gaap_InvestmentIncomeInterest (64)us-gaap_InvestmentIncomeInterest
Interest expense, net of portion capitalized (Note 4) 533us-gaap_InterestExpense 482us-gaap_InterestExpense 532us-gaap_InterestExpense
Other (income) expense, net (70)us-gaap_OtherNonoperatingIncomeExpense 2,498us-gaap_OtherNonoperatingIncomeExpense 1,626us-gaap_OtherNonoperatingIncomeExpense
Earnings before provision for taxes on income 20,563us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments [1] 15,471us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments [2] 13,775us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments [3]
Provision for taxes on income (Note 8) 4,240us-gaap_IncomeTaxExpenseBenefit 1,640us-gaap_IncomeTaxExpenseBenefit 3,261us-gaap_IncomeTaxExpenseBenefit
Net earnings 16,323us-gaap_ProfitLoss 13,831us-gaap_ProfitLoss 10,514us-gaap_ProfitLoss
Add: Net loss attributable to noncontrolling interest 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 339us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net earnings attributable to Johnson & Johnson $ 16,323us-gaap_NetIncomeLoss $ 13,831us-gaap_NetIncomeLoss $ 10,853us-gaap_NetIncomeLoss
Net earnings per share attributable to Johnson & Johnson (Notes 1 and 15)      
Basic $ 5.80us-gaap_EarningsPerShareBasic $ 4.92us-gaap_EarningsPerShareBasic $ 3.94us-gaap_EarningsPerShareBasic
Diluted $ 5.70us-gaap_EarningsPerShareDiluted $ 4.81us-gaap_EarningsPerShareDiluted $ 3.86us-gaap_EarningsPerShareDiluted
Cash dividends per share $ 2.76us-gaap_CommonStockDividendsPerShareCashPaid $ 2.59us-gaap_CommonStockDividendsPerShareCashPaid $ 2.40us-gaap_CommonStockDividendsPerShareCashPaid
Average shares outstanding (Notes 1 and 15)      
Basic 2,815.2us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 2,809.2us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 2,753.3us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Diluted 2,863.9us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 2,877.0us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 2,812.6us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
[1] Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. Includes an additional year of the Branded Prescription Drug Fee of $220 million in the Pharmaceutical segment.
[2] Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
[3] Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices segments, respectively. The Medical Devices segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.